[一种新型药物向VIPR2,以调节乳腺癌的迁移和扩散]
Satoshi Asano1, Kotaro Sakamoto2, Yukio Ago1
1Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica
|April 30, 2025
概括
血管活性肠道 (VIP) 受体2 (VIPR2) 驱动乳腺癌细胞的增殖和迁移. 用对抗剂KS-133向VIPR2显示了治疗乳腺癌亚型的潜力,这些亚型对当前疗法有抗性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 目前分子向乳腺癌药物对具有低表皮生长因子受体水平的亚型效果较差.
- 在这些特定的乳腺癌亚型中,需要新的治疗点.
- 血管活性肠 (VIP) 受体2 (VIPR2) 是一种G蛋白合受体,在各种器官中发现,在乳腺癌中升高.
研究的目的:
- 研究VIPR2在乳腺癌细胞增殖和迁移中的作用.
- 确定VIPR2作为乳腺癌治疗的潜在治疗标.
主要方法:
- 研究了乳腺癌细胞中的VIP-VIPR2信号通路.
- 利用选择性VIPR2对手 (KS-133) 来评估其对细胞行为的影响.
- 分析了下游的信号通路,包括PI3Kγ,cAMP/PKA/ERK和PI3K/AKT/GSK-3β.
主要成果:
- VIP-VIPR2信号通过激活PI3Kγ和调节伪形成,促进乳腺癌细胞迁移.
- 通过cAMP/PKA/ERK和PI3K/AKT/GSK-3β通路调节cyclin D1水平和G1/S细胞周期过渡,VIP-VIPR2信号控制细胞增殖.
- 用KS-133治疗有效抑制了VIP诱导的乳腺癌细胞的增殖和迁移.
结论:
- VIPR2是一种新的分子标,与乳腺癌进展有关.
- VIP-VIPR2通路代表了一种控制乳腺癌细胞增殖和迁移的新机制.
- KS-133是乳腺癌治疗的潜在向药物,特别是在对现有疗法耐药的亚型.
更多相关视频
07:03Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Published on: February 3, 2021
2.6K
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
28.4K
相关概念视频
Cancer Cell Migration through Invadopodia
2.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
